SubHero Banner

Lynparza® (olaparib) – New indication

May 20, 2020 - AstraZeneca and Merck announced the FDA approval of Lynparza (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with Xtandi® (enzalutamide) or abiraterone.

Download PDF